NCT05403710

Botulinum Toxin Therapy in Hidradenitis Suppurativa

Targeting Nociceptors in Hidradenitis Suppurativa

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: University of Massachusetts, Worcester · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will build on data from mice and humans implicating TRPV1 nociceptors in the pathogenesis of the type-17 chronic inflammatory skin disease Hidradenitis Suppurativa (HS). In this study, the investigators will test the hypothesis that inhibiting neuropeptide activity with botulinum toxin reduces pathogenic inflammation.

Detailed description

Botulinum toxin prevents vesicle fusion at nerve terminals thereby inhibiting neuropeptide release. The investigators will collect punch biopsies of lesional skin from HS patients before, and 1-2 months after botulinum toxin treatment (50U per axilla in 10 injections of 0.1mL) then perform flow cytometric, transcriptomic, and microscopic analysis of skin to determine if nonselective inhibition of neuropeptide release diminishes IL-17 driven skin inflammation.

Conditions

• Hidradenitis Suppurativa
• Hyperhidrosis

Interventions

Type	Name	Description
DRUG	Botulinum toxin	Administration of botulinum toxin (50 units/100cm2 injected intradermally) into lesional skin

Timeline

• Start date: 2022-06-07
• Primary completion: 2028-04-30
• Completion: 2028-04-30
• First posted: 2022-06-03
• Last updated: 2025-09-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study